Ximbio aims to change the way research reagents are searched, sourced and shared
Ximbio (www.ximb.io), an online reagents portal for the life science community which originates from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, and UMIP, The University of Manchester’s agent for IP commercialisation, announce Ximbio will be exhibiting at The University of Manchester on 20th and 21st January 2015.
Researchers interested in learning how Ximbio can help increase the global visibility of their new and already developed research tools, and help manage requests for those reagents, are invited to contact Dr Melanie Hardman from Ximbio (E: email@example.com, T: 020 3469 6449 or 07733 220175) to arrange a one-to-one discussion. Alternatively Melanie will be available at the Ximbio exhibition stand on Tuesday 20th January at the Michael Smith Building, and on Wednesday 21st January at the MIB John Garside Building.
Ximbio is an online portal for the life science community to exchange knowledge and trade reagents. Researchers can virtually deposit reagents, to raise their profile and share research globally. The Ximbio community benefits from Ximbio’s existing relationships with more than 100 life science reagents companies. Deposited reagents can be ‘tagged’ with details of the laboratory where they were developed, to make it easier for future users to cite the originating source in publications. Researchers can also use Ximbio to help make an informed decision about where to source a product from, and share experiences of using specific reagents with others.
Melanie Hardman, Head of Ximbio, commented: “We are excited to visit The University of Manchester, in collaboration with UMIP. We created Ximbio to be a place where the reagent community can be unified, maximising the visibility and impact of all research reagents and making them more widely and easily available, to help accelerate life science research. We look forward to working with Manchester based researchers.”
Dr. Ed Maughfling, Express Licensing Manager, UMIP, said: “Research reagents represent one of four key product areas (along with software, clinical questionnaires and images) of UMIP’s Express IP portfolio (http://umip.com/what-is-express-ip/). As part of UMIP’s strategy of developing either online sales capability (www.click2go.umip.com) or working with a preferred licensing partner, UMIP and Ximbio hope to work together to identify, disseminate and commercialise research reagents developed at The University of Manchester.”
Flyer download Ximbio visit
Zyme Communications Ltd.
Lorna Cuddon / Katie Odgaard
Tel: +44 (0)7811 996 942 / +44 (0)7787 502 947
About Ximbio (www.ximb.io)
Ximbio will change the way life science reagents are searched, sourced and shared.
Through Ximbio researchers and technology transfer offices can virtually deposit their reagents free of charge to an online portal. Each reagent record can be linked to the originating inventor, enabling scientists and institutions to be credited for their work.
- Life science reagents companies can use Ximbio to easily source new products to augment their portfolios via a straightforward commercialisation process.
- Ximbio offers scientists looking for a specific reagent with a fully searchable database, extensive datasheets, peer reviews and supplier options.
Ximbio is owned by Cancer Research Technology (CRT). A share of product-based revenues is returned to the depositing institution.
Ximbio will focus on all areas of biology, and will broaden the range of tools available to scientists globally, to support and advance life science research.
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.